Nuclear uptake and dosimetry of 64Cu-labeled chelator-somatostatin conjugates in an SSTr2-transfected human tumor cell line

Journal of Nuclear Medicine

Volumn 48, Issue 8, 2007, Pages 1390-1396

  Eiblmaier, Martin ^a   Andrews, Rebecca ^b   Laforest, Richard ^a   Rogers, Buck E ^b   Anderson, Carolyn J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

64Cu; Dosimetry; Somatostatin analog; Somatostatin receptor; Targeted radiotherapy

Indexed keywords

1,4,8,11 TETRAAZACYCLOTETRADECANE 1,4,8,11 TETRAACETIC ACID CU 64; 4,11 BIS(CARBOXYMETHYL) 1,4,8,11 TETRAAZABICYCLO[6.6.2]HEXADECANE CU 64; CHELATING AGENT; COPPER 64; CYCLAM; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL KILLING; CELL NUCLEUS; CONTROLLED STUDY; DOSIMETRY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG UPTAKE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HUMAN CELL; INTERNALIZATION; PRIORITY JOURNAL; RADIOCHEMISTRY;

CELL LINE, TUMOR; CELL NUCLEUS; CHELATING AGENTS; COPPER RADIOISOTOPES; HUMANS; ISOTOPE LABELING; RADIOMETRY; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TRANSFECTION;

EID: 34547744847     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.039990     Document Type: Article

References (25)

1. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-731.
2. Krenning EP, Kooij PPM, Pauwels S, et al. Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion. 1996;57(suppl. 1):57-61.
3. 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res. 1998;58:437-441.
4. 90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med. 1998;25:668-674.
5. 3]octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer. 2001;92:628-633.
6. Anderson CJ, Jones LA, Bass LA, et al. Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats. J Nucl Med. 1998;39:1944-1951.
7. 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive tumor-bearing rat model. Clin Cancer Res. 1999;5:3608-3616.
8. 90Y-SMT 487 (OctreoTher™) in patients with diffuse somatostatin receptor positive liver metastases. Cancer Biother Radiopharm. 2003;18:581-588.
9. 90Y-labeled somatostatin analogs. J Nucl Med. 2005;46(suppl 1):13S-17S.
10. Pless M, Waldherr C, Maecke H, Buitrago C, Herrmann R, Mueller-Brand J. Targeted radiotherapy for small cell lung cancer using 90yttrium-DOTATOC, an yttrium-labelled somatostatin analogue: a pilot trial. Lung Cancer. 2004;45:365-371.
11. 177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30:417-422.
12. Froidevaux S, Eberle AN. Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers. 2002;66:161-183.
13. Connett JM, Anderson CJ, Guo LW, et al. Radioimmunotherapy with a Cu-64-labeled monoclonal antibody: a comparision with Cu-67. Proc Natl Acad Sci USA. 1996;93:6814-6818.
14. 64Cu-labeled MAb 1A3 in a colon cancer model. Clin Cancer Res. 1999;5:3207s-3212s.
15. Wang M, Caruano AL, Lewis MR, Meyer LA, VanderWaal RP, Anderson CJ. Subcellular localization of radiolabeled somatostatin analogues: implications for targeted radiotherapy of cancer. Cancer Res. 2003;63:6864-6869.
16. Parry JJ, Eiblmaier M, Andrews R, et al. Characterization of somatostatin receptor subtype 2 expression in stably transfected A-427 human cancer cells. Mol Imaging. 2007;6:56-67.
17. 3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res. 2004;10:8674-8682.
18. Goddu SM, Howell RW, Bouchet LG, Bolch WE, Rao DV. MIRD Cellular S Values: Self-Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Monoenergetic Electron and Alpha Particle Emitters Incorporated into Different Cell Compartments. New York, NY: Society of Nuclear Medicine; 1997.
19. Reubi JC, Schar J-C, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273-282.
20. 64Cu-labeled somatostatin analogs in vitro and in a tumor-bearing rat model: evaluation of new derivatives for PET imaging and targeted radiotherapy. J Med Chem. 1999;42:1341-1347.
21. 3-octreotate: a new somatostatin analog with improved target tissue uptake. Nucl Med Biol. 1999;26:267-273.
22. Woodin KS, Heroux KJ, Boswell CA, et al. Kinetic inertness and electrochemical behavior of Cu(II) tetraazamacrocyclic complexes: possible implications for in vivo stability. Eur J Inorg Chem. 2005;4829-4833.
23. Boswell CA, Sun X, Niu W, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem. 2004;47:1465-1474.
24. Hornick CA, Anthony CT, Hughey S, Gebhardt BM, Espenan GD, Woltering EA. Progressive nuclear translocation of somatostatin analogs. J Nucl Med. 2000;41:1256-1263.
25. Nayak T, Norenberg J, Anderson T, Atcher R. A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro. Cancer Biother Radiopharm. 2005;20:52-57.